Plus, Tessellate BIO, led by former Large Pharma execs, comes out of stealth.
Lumales Bioscience will get $16M to advertvance C. diff therapy: The Dehalfment of Defense awarded $16.2 million to the Seattle-based company, which is developing an oral drug to deal with and prevent infections with C. difficile. It plans to start out enrolling 375 patients in a late-stage trial for LMN-201 by the tip of the yr.
Flashlevel’s $10M: Flashlevel Therapeutics on Tuesday announced a $10 million seed spherical, led by Riyadh-based Beta Lab. The funds are expected to assist advertvance the company’s first cancer therapy and select a second candidate. Flashlevel’s platkind relies on work out of Chad Mirkin’s lab at Northwestern University’s International Institute for Nanotechnology.
Unlock this text immediately by changing into a free subscriber.
You’ll get entry to free articles every month, plus you may customise what newsletters get delivered to your inbox every week, together with breaking information.
